Skip to main content
OpenTrials
Completed

NCT Number: NCT07264465

A Clinical Trial to Evaluate the Effects of a Chickpea Pasta on Gut Health, Blood Glucose, and Overall Health

This is a single-arm, 12-week pilot study evaluating the effects of a chickpea pasta on gut microbiome diversity, gastrointestinal health, and blood biomarkers. The study will involve 12 participants consuming the test product five times per week, with questionnaires, microbiome testing, blood testing, and waist measurements collected at defined timepoints.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–44 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female
  • Be aged 21-44.
  • Anyone currently experiencing issues regarding all of the following:
  • Struggling to balance taste with health and convenience.
  • Struggling to eat healthy due to a busy lifestyle.
  • Self-reported poor gut health (including bloating, abdominal discomfort, and gas).
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • If taking oral over-the-counter supplements or herbal remedies targeted at gut health, blood sugar, and overall health and well-being, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration.
  • Not planning on introducing any products or any new forms of prescription medication or supplements that target gut health, blood sugar, or overall health and well-being for the study duration.
  • Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
  • Anyone who has tried pasta alternatives in the past (e.g., made of chickpeas, lentils, beans, etc.) or, if not, is open to trying them.
  • Anyone with access to a 3-quart pasta pot that can be used 5 times weekly.
  • Resides in the United States.
  • Not currently partaking in another research study and will not be partaking in any other research study for the next 12 weeks and at any point during this study's duration.

Exclusion criteria

  • Has been diagnosed with Type 1 or Type 2 diabetes.
  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone with known severe allergic reactions.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
  • Anyone unwilling to follow the study protocol.
  • Anyone who has undergone any surgeries or invasive treatments in the last six months.
  • Anyone planning to undergo any surgeries or invasive treatments during the study period.
  • Anyone with a known history of severe digestive disorders like acid reflux, irritable bowel syndrome (IBS), irritable bowel disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
  • Anyone with a history of substance abuse.
  • Anyone who eats a pasta alternative (like chickpea pasta) one or more times per week.
  • Follows a specific diet, such as ketogenic, paleo, or gluten-free

Treatment and study plan

Chickpea Pasta

Dietary Supplement

The intervention is intended to assess the effects of a high-fiber, legume-based dietary product on gut microbiome diversity, gastrointestinal function, and metabolic biomarkers.

Primary outcomes

  1. Change in gut microbiome diversity

    Time frame: Baseline and Week 12

    Gut microbiome diversity will be assessed using microbiome testing of stool samples. This outcome will evaluate the effect of the intervention on microbial community richness and composition.

  2. Change in gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Assessed using the GSRS to evaluate symptoms such as bloating and abdominal discomfort.

  3. Change in blood biomarkers regarding Hemoglobin A1C

    Time frame: Baseline and Week 12

    Measured via blood tests including Hemoglobin A1C with eAG.

  4. Change in blood biomarkers regarding CMP-14

    Time frame: Baseline and Week 12

    Measured via blood tests including CMP-14, lipid panel, and serum iron to assess metabolic and cardiovascular health indicators.

  5. Change in stool quality using the Bristol Stool Scale (BSS)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Assessed using the BSS to evaluate stool consistency and form.

Secondary outcomes

  1. Participant-reported perceptions of gut and overall health

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Evaluated through self-reported questionnaires on perceived gut health, weight management, bloating, confidence in clothes, and overall well-being.

  2. Change in waist circumference

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Participants will self-measure and report waist circumference to assess changes in central adiposity over the course of the intervention.

Sponsors and collaborators

Lead sponsor

Banza LLC

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 4, 2025
Registry last updated
Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.